Erasca Inc Total Assets
Erasca Inc total assets. Based on the latest financial reports, Erasca Inc (ERAS) holds total assets worth $435.05 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Erasca Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Erasca Inc (2019–2025)
Total assets of Erasca Inc from 2019 to 2025. This chart illustrates how Erasca Inc's total assets have evolved over time, based on quarterly financial data. See ERAS stock price and chart for real-time trading data and today's change.
Erasca Inc - Asset Composition Analysis
Erasca Inc Total Assets Breakdown (December 2025)
Erasca Inc total assets breakdown as of December 2025. Erasca Inc's total assets of $435.05 Million consist of 72.3% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.6% |
| Accounts Receivable | $2.50 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Erasca Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Erasca Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Erasca Inc's current assets represent 72.3% of total assets in 2025, a decrease from 92.1% in 2019.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2025, down from 53.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Erasca Inc Competitors by Total Assets
Key competitors of Erasca Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Erasca Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.29 | 11.04 | 25.13 |
| Quick Ratio | 8.29 | 11.04 | 25.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $244.87 Million | $282.51 Million | $472.73 Million |
Erasca Inc - Advanced Valuation Insights
This section examines the relationship between Erasca Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.66 |
| Latest Market Cap to Assets Ratio | 12.93 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | $396.15 Million |
| Market Capitalization | $5.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Erasca Inc's assets at a significant premium (12.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Erasca Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Erasca Inc (2019–2025)
The table below shows the annual total assets of Erasca Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $396.15 Million | -21.17% |
| 2024-12-31 | $502.53 Million | +27.13% |
| 2023-12-31 | $395.30 Million | -23.23% |
| 2022-12-31 | $514.91 Million | +2.69% |
| 2021-12-31 | $501.42 Million | +301.69% |
| 2020-12-31 | $124.83 Million | +124.86% |
| 2019-12-31 | $55.51 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more